FRM
DFTX

Fox Run Management’s Definium Therapeutics DFTX Stock Holding History

Fox Run Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,557
Closed -$255K – 1164
2026
Q1 		$255K Sell
14,557
-16,151
-53% -$274K 0.04% 671
2025
Q4 		$411K Sell
30,708
-20,984
-41% -$260K 0.06% 579
2025
Q3 		$609K Buy
+51,692
New +$482K 0.1% 409

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fox Run Management's DFTX Position: Q2 2026 in Review

Fox Run Management sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 14,557 shares — an estimated $255K sold.

Fox Run Management first reported a position in DFTX in Q3 2025 and held it in 3 quarters. The position peaked at $609K in Q3 2025. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Fox Run Management reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 14,557 Definium Therapeutics shares in Q2 2026, an estimated $255K.
  • Fox Run Management first reported a position in Definium Therapeutics in Q3 2025 and held it in 3 quarters.
  • Fox Run Management's Definium Therapeutics position peaked at $609K in Q3 2025.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.